ATE530533T1 - Verfahren zur synthese heterocyclischer verbindungen - Google Patents

Verfahren zur synthese heterocyclischer verbindungen

Info

Publication number
ATE530533T1
ATE530533T1 AT06760144T AT06760144T ATE530533T1 AT E530533 T1 ATE530533 T1 AT E530533T1 AT 06760144 T AT06760144 T AT 06760144T AT 06760144 T AT06760144 T AT 06760144T AT E530533 T1 ATE530533 T1 AT E530533T1
Authority
AT
Austria
Prior art keywords
solvent
synthesis
heterocyclic compounds
nitroaniline
methylpiperazine
Prior art date
Application number
AT06760144T
Other languages
English (en)
Inventor
Gabriel Calvin
Eric Harwood
David Ryckman
Shuguang Zhu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE530533T1 publication Critical patent/ATE530533T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06760144T 2005-05-17 2006-05-17 Verfahren zur synthese heterocyclischer verbindungen ATE530533T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68189305P 2005-05-17 2005-05-17
PCT/US2006/019349 WO2006125130A1 (en) 2005-05-17 2006-05-17 Methods for synthesizing heterocyclic compounds

Publications (1)

Publication Number Publication Date
ATE530533T1 true ATE530533T1 (de) 2011-11-15

Family

ID=37431595

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06760144T ATE530533T1 (de) 2005-05-17 2006-05-17 Verfahren zur synthese heterocyclischer verbindungen

Country Status (15)

Country Link
US (1) US8222413B2 (de)
EP (2) EP2465857B1 (de)
JP (2) JP5545925B2 (de)
KR (1) KR101324863B1 (de)
CN (1) CN101223157B (de)
AT (1) ATE530533T1 (de)
AU (1) AU2006247062A1 (de)
BR (1) BRPI0610355A2 (de)
CA (1) CA2608087C (de)
ES (1) ES2376347T3 (de)
MX (1) MX2007014381A (de)
PL (1) PL1888556T3 (de)
PT (1) PT1888556E (de)
RU (1) RU2437878C2 (de)
WO (1) WO2006125130A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE530533T1 (de) * 2005-05-17 2011-11-15 Novartis Ag Verfahren zur synthese heterocyclischer verbindungen
JP5541454B2 (ja) * 2009-09-16 2014-07-09 Jsr株式会社 液晶配向剤および液晶表示素子
KR102087662B1 (ko) 2018-06-20 2020-03-11 강원대학교산학협력단 4-[[4-[3-(사이클로프로필메톡시)-4-(디플루오로메톡시)페닐]-2-티아졸릴]아미노]페놀 화합물을 유효성분으로 포함하는 만성폐쇄성 폐질환의 예방 또는 치료용 조성물
KR102087661B1 (ko) 2018-07-27 2020-03-11 강원대학교산학협력단 Gebr―7b 화합물을 유효성분으로 포함하는 만성폐쇄성 폐질환의 예방 또는 치료용 조성물

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663606A (en) 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
DE3248043A1 (de) 1982-12-24 1984-06-28 Bayer Ag, 5090 Leverkusen Fluorogene phosphorsaeureester, verfahren zu deren herstellung sowie verfahren und mittel zum nachweis und zur fluorometrischen bestimmung von phosphaten
US4659657A (en) 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
DE3634066A1 (de) 1986-10-07 1988-04-21 Boehringer Mannheim Gmbh Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel
JPH07121937B2 (ja) 1987-03-18 1995-12-25 大塚製薬株式会社 カルボスチリル誘導体
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
DE3932953A1 (de) 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9107742D0 (en) 1991-04-11 1991-05-29 Rhone Poulenc Agriculture New compositions of matter
GB9108369D0 (en) 1991-04-18 1991-06-05 Rhone Poulenc Agriculture Compositions of matter
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en) 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5856115A (en) 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機el素子
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
WO1995018801A1 (en) 1994-01-08 1995-07-13 Rhone-Poulenc Agriculture Ltd. Benzimidazolyl quinoline-3-carboxylate derivatives, intermediates thereto, and their use as herbicides
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997034876A1 (en) 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
EP0934307B1 (de) 1996-06-19 2011-04-27 Aventis Pharma Limited Substituierte azabicyclische verbindungen und ihre verwendung als inhibitoren des tnf und der cyclischen amp phosphodiestrase
KR20000022040A (ko) 1996-06-20 2000-04-25 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 약학적 활성 제제를 제공하기 위한 화합물, 방법 및 그의 용도
US6809097B1 (en) 1996-09-25 2004-10-26 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as VEGF
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
NZ505921A (en) 1998-03-31 2003-08-29 Warner Lambert Co 1-[5-(2,6-Dimethylpiperidino)pentyl] substituted quinolone serine protease inhibitors and their use for treating thrombin related disorders
EP1086705A4 (de) 1998-05-20 2002-02-06 Kyowa Hakko Kogyo Kk Inhibitoren der aktivität des vaskularen endothelialen wachstumsfaktors
US6489344B1 (en) 1998-06-19 2002-12-03 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2000000481A1 (en) 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
FR2781218B1 (fr) 1998-07-15 2001-09-07 Lafon Labor Compositions pharmaceutiques comprenant des 2-quinolones
US6174912B1 (en) 1998-08-21 2001-01-16 Dupont Pharmaceuticals Company Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
WO2000020400A1 (en) 1998-10-05 2000-04-13 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
KR100373203B1 (ko) 1999-03-31 2003-02-25 주식회사 엘지화학 새로운 큐마린계 착물 및 이를 이용한 유기 발광 소자
BR0010482A (pt) 1999-05-21 2002-04-23 Bristol Myers Squibb Co Inibidores pirrolotriazìnicos de cinases
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
KR100298572B1 (ko) 1999-08-19 2001-09-22 박찬구 카바아닐라이드로부터 4-니트로디페닐아민과 4-니트로소디페닐아민의 제조방법
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2387351C (en) 1999-10-19 2009-09-08 Merck & Co., Inc. Indole derivatives as tyrosine kinase inhibitors
EP1248642A4 (de) 2000-01-18 2005-05-18 Ludwig Inst Cancer Res Peptidomimetischer inhibitor von vegf sowie vegf-c und -d
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
EP1252308A2 (de) 2000-01-19 2002-10-30 Parkash S. Gill Pharmazeutische zubereitungen und behandlungsmethoden, die auf vegf antisense-oligonucleotiden basieren
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2400923A1 (en) 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US7179912B2 (en) * 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
PT1313734E (pt) 2000-09-01 2010-02-09 Novartis Vaccines & Diagnostic Derivados aza heterocíclicos e sua utilização terapêutica
ES2302106T3 (es) * 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
JP2004509949A (ja) 2000-09-26 2004-04-02 ザ ユニバーシティ オブ アリゾナ ファウンデーション 化合物および癌またはウイルス性感染症治療におけるその使用方法
US6656942B2 (en) 2000-10-17 2003-12-02 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
EP1401831A1 (de) 2001-07-03 2004-03-31 Chiron Corporation Indazol-benzimidazol-derivate als tyrosin- und serin/threonin-kinase-inhibitoren
WO2003033472A1 (fr) 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
BR0313743A (pt) 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
WO2004030620A2 (en) 2002-09-30 2004-04-15 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
BR0316229A (pt) 2002-11-13 2005-10-04 Chiron Corp Métodos de tratamento de câncer e métodos relacionados
US7189716B2 (en) 2003-01-03 2007-03-13 Bristol-Myers Squibb Company Tyrosine kinase inhibitors
WO2004063170A1 (en) * 2003-01-09 2004-07-29 University Of Delhi A process for the synthesis of bisbenzimidazoles and its derivations
EP1608369B1 (de) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Verwendung von organischen verbindungen zur immunpotenzierung
EP2762475A1 (de) * 2003-11-07 2014-08-06 Novartis Vaccines and Diagnostics, Inc. Pharmazeutisch akzeptable Salze von Chinolinverbindungen und ihre medizinische Verwendung
JP5019884B2 (ja) 2004-02-20 2012-09-05 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 炎症プロセスおよび転移プロセスの調節
ATE530533T1 (de) * 2005-05-17 2011-11-15 Novartis Ag Verfahren zur synthese heterocyclischer verbindungen

Also Published As

Publication number Publication date
ES2376347T3 (es) 2012-03-13
EP2465857A1 (de) 2012-06-20
AU2006247062A1 (en) 2006-11-23
KR101324863B1 (ko) 2013-11-01
PT1888556E (pt) 2012-02-03
CN101223157A (zh) 2008-07-16
US8222413B2 (en) 2012-07-17
KR20080026106A (ko) 2008-03-24
RU2437878C2 (ru) 2011-12-27
WO2006125130A1 (en) 2006-11-23
JP2014012682A (ja) 2014-01-23
EP1888556A4 (de) 2009-12-02
US20110046376A1 (en) 2011-02-24
EP1888556B1 (de) 2011-10-26
JP5545925B2 (ja) 2014-07-09
EP2465857B1 (de) 2014-06-04
EP1888556A1 (de) 2008-02-20
RU2007146394A (ru) 2009-06-27
CA2608087A1 (en) 2006-11-23
PL1888556T3 (pl) 2012-03-30
CA2608087C (en) 2013-12-10
BRPI0610355A2 (pt) 2010-06-15
JP2008540675A (ja) 2008-11-20
MX2007014381A (es) 2008-02-06
CN101223157B (zh) 2013-03-06

Similar Documents

Publication Publication Date Title
NO20071045L (no) Fremgangsmate for fremstilling av maursyre.
UA83910C2 (ru) Способ получения 5-гидрокси-4-тиометилпиразольного соединения
ATE477234T1 (de) Synthese von phenolischen estern von hydroxymethylphenolen
HK1114101A1 (de)
ATE530533T1 (de) Verfahren zur synthese heterocyclischer verbindungen
BRPI0511109A (pt) método fácil para sintetizar compostos de baccatin iii
ZA201003751B (en) Process for the synthesis of propargylated aminoindan derivatives
ATE530186T1 (de) Polyacetylenische verbindungen
ATE529413T1 (de) Verfahren zur synthese von aryloxydiaminopyrimidinen
DE602006005349D1 (de) Verfahren zur herstellung von hydrazon-derivaten
ATE520685T1 (de) Verbessertes verfahren zur herstellung von moxonidin
DE502007001154D1 (de) Verfahren zur Trennung von Zirkonium und Hafnium
ATE427297T1 (de) Verfahren zur herstellung von beta- aminopropionsaurederivaten
BRPI0514313A (pt) processo para sintetizar um composto, e, composto
RU2003122994A (ru) Комплексное соединение 6-метилурацила с янтарной кислотой, проявляющее антигипоксическую активность и способ его получения
AR068925A1 (es) Un proceso mejorado para preparar un derivado de 2,4. - tiazolidindiona
TH76675A (th) กระบวนการสำหรับการสังเคราะห์อินโดลที่ถูก n-อัลคิเลเต็ดที่ถูกแทนที่ c-2, c-3 ที่เป็นประโยชน์เป็นสารยับยั้ง cpla2
ATE492556T1 (de) Verfahren zur glycosidierung von colchicin und thiocolchicin
TH116170A (th) กระบวนการใหม่สำหรับการสังเคราะห์อะโกเมลาทีน
AR065108A1 (es) Proceso para elaborar (r)-5-(2-aminoetil)-1-(6,8-difluorocromo-3-il)-1,3-dihidroimidazol-2-tiona
TH96061B (th) อิมิดาโซลชนิดถูกแทนที่
TH79586B (th) สารประกอบอินทรีย์
TH127212A (th) N1-ซับทิทิวเทด-5-ฟลูออโร-2-ออกโซพิริมิดิโนน-1(2h)-คาร์บอกแซมีด
TH123656B (th) ตัวยับยั้งของ iap
TH95364B (th) ไตรเพนทิลซิเตรทและการนำไปใช้

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1888556

Country of ref document: EP